Specifically, since the correlation of the IGF-IR expression and patient outcome in human breast cancer is conflicting [66], the IGF-I induced gene expression signature showing the functional effects of IGF-I axis stimulation, which is correlated with the patients' clinical outcome, might be of interest when selecting patients who might benefit best from IGF-I blocking therapies. The gene discussed is IGF1R; the disease is breast carcinoma.